Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:PSTI
- CUSIP: N/A
- Web: www.pluristem.com
Capitalization:- Market Cap: $142.31 million
- Outstanding Shares: 97,473,000
Average Prices:- 50 Day Moving Avg: $1.20
- 200 Day Moving Avg: $1.28
- 52 Week Range: $1.04 - $1.66
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.57
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.31 per share
- Price / Book: 5.03
Profitability:- EBIDTA: ($25,840,000.00)
- Return on Equity: -89.81%
- Return on Assets: -72.46%
Debt:- Current Ratio: 5.36%
- Quick Ratio: 5.36%
Misc:- Average Volume: 327,442 shs.
- Beta: 0.1
- Short Ratio: 5.82
Frequently Asked Questions for Pluristem Therapeutics (NASDAQ:PSTI)
What is Pluristem Therapeutics' stock symbol?
Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."
How were Pluristem Therapeutics' earnings last quarter?
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) released its earnings results on Thursday, November, 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.04. The firm earned $0.10 million during the quarter, compared to analyst estimates of $0.10 million. View Pluristem Therapeutics' Earnings History.
When will Pluristem Therapeutics make its next earnings announcement?
Where is Pluristem Therapeutics' stock going? Where will Pluristem Therapeutics' stock price be in 2017?
3 equities research analysts have issued 12 month target prices for Pluristem Therapeutics' stock. Their predictions range from $2.00 to $6.00. On average, they expect Pluristem Therapeutics' stock price to reach $3.83 in the next year. View Analyst Ratings for Pluristem Therapeutics.
What are analysts saying about Pluristem Therapeutics stock?
Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
- 1. Maxim Group analysts commented, "Summary Pluristem announced that Austria’s regulatory health agency, the Austrian Agency for Health and Food Safety (AGES), has cleared the study to begin enrollment in Austria. The PIII trial is currently enrolling patients in the U.S., U.K., and Germany. Pluristem is focused on showing the benefits of therapy in prolonging the time to an event. If patients can keep a limb a year longer, is the therapy viable and does it create value. We do believe the current statistical plan is well designed to show if a difference exists in the time to event analysis. What will be critical will be if US regulators will accept time to event in place of AFS for approval. It stands to reason that a treatment effect which prolongs time to event, (as is the standard on oncology) could suffice for approval in CLI (Critical Limb Ischemia). i.e. if the treated group keeps limbs longer, is the therapy approvable one and is there benefit? We must also consider changes in the regulatory landscape and what impact the adaptive pathway and 21st Century Act might have on regenerative medicine – cell therapy approval timelines." (7/10/2017)
- 2. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (4/13/2017)
Who are some of Pluristem Therapeutics' key competitors?
Some companies that are related to Pluristem Therapeutics include Protagonist Therapeutics (PTGX), Codexis (CDXS), Curis (CRIS), Nabriva Therapeutics AG (NBRV), Organovo Holdings (ONVO), Organovo Holdings (ONVO), Horizon Discovery Group PLC (HZD), Chromadex Corp (CDXC), Advaxis (ADXS), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), Regulus Therapeutics (RGLS), CTI BioPharma Corp. (CTIC) and GTx (GTXI).
Who are Pluristem Therapeutics' key executives?
Pluristem Therapeutics' management team includes the folowing people:
- Yaky Yanay, Chairman of the Board, Chief Executive Officer
- Zalman Aberman, President, Co-Chief Executive Officer, Director
- Erez Egozi, Chief Financial Officer
- Doron Shorrer CPA, Lead Independent Director
- Moria Kwiat, Director
- Hava Meretzki, Director
- Israel Ben-Yoram, Independent Director
- Issac Braun, Independent Director
Who owns Pluristem Therapeutics stock?
Pluristem Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (1.04%), California Public Employees Retirement System (0.19%) and Harel Insurance Investments & Financial Services Ltd. (0.10%). Company insiders that own Pluristem Therapeutics stock include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman. View Institutional Ownership Trends for Pluristem Therapeutics.
How do I buy Pluristem Therapeutics stock?
Shares of Pluristem Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pluristem Therapeutics' stock price today?
One share of Pluristem Therapeutics stock can currently be purchased for approximately $1.56.
MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $3.83 (145.73% upside) |
Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/19/2017 | HC Wainwright | Reiterated Rating | Buy | $3.50 | Low |  |
| 9/5/2017 | Maxim Group | Reiterated Rating | Buy | $2.00 | Medium | |
| 1/10/2017 | FBR & Co | Reiterated Rating | Buy | | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)Earnings History by Quarter for Pluristem Therapeutics (NASDAQ PSTI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | ($0.08) | | | | | N/A | |
| 11/6/2014 | | ($0.13) | ($0.09) | $0.10 million | $0.10 million | View | N/A | |
| 10/6/2014 | | ($0.13) | ($0.09) | | | View | N/A | |
| 9/11/2014 | | ($0.15) | ($0.09) | $0.10 million | $0.09 million | View | N/A | |
| 5/8/2014 | | ($0.14) | ($0.14) | $0.20 million | $0.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS
Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pluristem Therapeutics (NASDAQ:PSTI)Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 4.47%
Insider Trades by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/22/2016 | Zami Aberman | CEO | Buy | 5,000 | $1.33 | $6,650.00 | |
| 2/18/2016 | Yaky Yanay | CFO | Buy | 5,000 | $1.20 | $6,000.00 | |
| 2/16/2016 | Yaky Yanay | CFO | Buy | 15,000 | $0.95 | $14,250.00 | |
| 2/15/2016 | Doron Shorrer | Director | Buy | 12,346 | $0.81 | $10,000.26 | |
| 2/12/2016 | Yaky Yanay | CFO | Buy | 5,000 | $0.83 | $4,150.00 | |
| 2/11/2016 | Israel Ben-Yoram | Director | Buy | 10,000 | $0.79 | $7,900.00 | |
| 2/11/2016 | Zami Aberman | CEO | Buy | 31,000 | $0.80 | $24,800.00 | |
| 11/16/2015 | Yaky Yanay | CFO | Buy | 10,000 | $1.52 | $15,200.00 | |
| 11/16/2015 | Zami Aberman | CEO | Buy | 9,900 | $1.49 | $14,751.00 | |
| 9/21/2015 | Israel Ben-Yoram | Director | Sell | 30,000 | $2.10 | $63,000.00 | |
| 9/21/2015 | Yaky Yanay | CFO | Buy | 10,000 | $2.11 | $21,100.00 | |
| 9/21/2015 | Zami Aberman | CEO | Buy | 25,500 | $2.11 | $53,805.00 | |
| 9/16/2015 | Yaky Yanay | CFO | Buy | 10,000 | $2.12 | $21,200.00 | |
| 9/15/2015 | Zami Aberman | CEO | Buy | 25,000 | $2.11 | $52,750.00 | |
| 11/11/2014 | Yaky Yanay | COO | Buy | 11,000 | $2.62 | $28,820.00 | |
| 11/11/2014 | Zami Aberman | CEO | Buy | 13,000 | $2.64 | $34,320.00 | |
| 9/22/2014 | Yaky Yanay | COO | Buy | 11,000 | $2.95 | $32,450.00 | |
| 9/22/2014 | Zami Aberman | CEO | Buy | 5,000 | $2.92 | $14,600.00 | |
| 9/21/2014 | Zami Aberman | CEO | Buy | 5,000 | $2.96 | $14,800.00 | |
| 9/17/2014 | Israel Ben-Yoram | Director | Buy | 5,000 | $2.82 | $14,100.00 | |
| 9/16/2014 | Boaz Gur-Lavie | CFO | Buy | 3,478 | $2.84 | $9,877.52 | |
| 9/16/2014 | Yaky Yanay | COO | Buy | 10,000 | $2.85 | $28,500.00 | |
| 9/16/2014 | Zami Aberman | CEO | Buy | 15,000 | $2.80 | $42,000.00 | |
| 6/18/2014 | Mark Germain | Director | Sell | 43,215 | $3.12 | $134,830.80 | |
| 1/17/2014 | Israel Ben-Yoram | Director | Sell | 35,625 | $4.51 | $160,668.75 | |
| 1/13/2014 | Israel Ben-Yoram | Director | Sell | 26,453 | $4.29 | $113,483.37 | |
| 1/13/2014 | Yaky Yanay | CFO | Sell | 69,850 | $4.29 | $299,656.50 | |
| 1/9/2014 | Yaky Yanay | CFO | Sell | 30,150 | $4.25 | $128,137.50 | |
| 1/8/2014 | Israel Ben-Yoram | Director | Sell | 44,797 | $4.12 | $184,563.64 | |
| 11/11/2013 | Nachum Rosman | Director | Sell | 67,244 | $3.27 | $219,887.88 | |
| 9/12/2013 | Israel Ben-Yoram | Director | Sell | 52,000 | $3.07 | $159,640.00 | |
| 5/20/2013 | Israel Ben-Yoram | Director | Sell | 45,429 | $3.03 | $137,649.87 | |
(Data available from 1/1/2013 forward)
Headline Trends for Pluristem Therapeutics (NASDAQ:PSTI)
Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
| Source: |
|
| Date | Headline |
|---|
 | FDA Grants Fast Track Designation To Pluristem's PLX-PAD For Treatment Of CLI
www.rttnews.com - September 20 at 7:59 AM |
 | Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP
finance.yahoo.com - September 20 at 7:59 AM |
 | Pluristem Therapeutics' (PSTI) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 19 at 3:14 PM |
 | Pluristem Therapeutics (PSTI) Reports U.S. FDA Grants Fast Track ... - StreetInsider.com
www.streetinsider.com - September 19 at 6:47 AM |
| Pluristem Wins Key FDA Approval
finance.yahoo.com - September 19 at 6:47 AM |
| Biotech Stocks Surging in September
finance.yahoo.com - September 19 at 6:47 AM |
| Pluristem Therapeutics (PSTI) versus Puma Biotechnology (PBYI) Head-To-Head Contrast
www.americanbankingnews.com - September 18 at 9:00 AM |
| Pluristem Therapeutics (PSTI) Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle ... - StreetInsider.com
www.streetinsider.com - September 14 at 9:34 AM |
 | Pluristem Therapeutics Inc.: A Biotech Company Inspired By Life - Seeking Alpha
seekingalpha.com - September 14 at 9:34 AM |
| Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration
finance.yahoo.com - September 13 at 8:02 AM |
| Should You Buy Pluristem Therapeutics Inc (PSTI)?
finance.yahoo.com - September 12 at 8:51 AM |
| Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights
finance.yahoo.com - September 12 at 8:51 AM |
| Pluristem Therapeutics (PSTI) & Bio-Path Holdings (BPTH) Financial Review
www.americanbankingnews.com - September 8 at 10:28 PM |
| HC Wainwright Reaffirms Buy Rating for Pluristem Therapeutics, Inc. (PSTI)
www.americanbankingnews.com - September 6 at 3:56 PM |
| Pluristem Therapeutics' (PSTI) "Buy" Rating Reiterated at Maxim Group
www.americanbankingnews.com - September 6 at 3:20 PM |
 | $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program - GlobeNewswire (press release)
globenewswire.com - September 6 at 7:31 AM |
| $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
finance.yahoo.com - September 6 at 7:31 AM |
| Pluristem Therapeutics, Inc. (PSTI) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - September 4 at 2:22 AM |
| ValuEngine Downgrades Pluristem Therapeutics, Inc. (PSTI) to Strong Sell
www.americanbankingnews.com - September 2 at 5:38 PM |
 | Health Care Sector Update for 08/16/2017: PSTI,IDXG,JAGX - Nasdaq
www.nasdaq.com - August 17 at 8:27 PM |
| Pluristem Therapeutics (PSTI) DOD to Conduct Studies of its PLX-R18 in New ARS Project for Use Before Radiation ... - StreetInsider.com
www.streetinsider.com - August 17 at 3:23 PM |
| HC Wainwright Reaffirms "Buy" Rating for Pluristem Therapeutics, Inc. (PSTI)
www.americanbankingnews.com - August 17 at 7:46 AM |
| ABIO To Report Data In Q1; IOVA Fired Up, PMD In Iowa, VRX All Cleared
www.rttnews.com - August 17 at 7:05 AM |
| Pluristem Therapeutics (PSTI) DOD to Conduct Studies of its PLX-R18 in New ARS Project for Use Before Radiation Exposure
www.streetinsider.com - August 17 at 7:05 AM |
| U.S. Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project for Use Before Radiation Exposure
finance.yahoo.com - August 17 at 7:05 AM |
| These Are the Hottest Stocks on the Planet Wednesday: URBN, TGT, PSTI, CSCO
finance.yahoo.com - August 17 at 7:05 AM |
| Pluristem Therapeutics, Inc. (PSTI) Given a $2.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - August 16 at 8:58 PM |
| Israeli Government to Support Pluristem's Marketing Activity in China – Ministry of Economy Awards Company “Smart ... - GlobeNewswire (press release)
globenewswire.com - August 10 at 7:04 AM |
| Israeli Government to Support Pluristem’s Marketing Activity in China – Ministry of Economy Awards Company “Smart Money” Grant
finance.yahoo.com - August 10 at 7:04 AM |
 | Pluristem stock rises 2.5% on mid-stage clinical trial results - MarketWatch
www.marketwatch.com - July 27 at 6:35 AM |
| New Data from ARS Study Shows Significant Hematological Deficiencies Even at Low Radiation Levels; PLX-R18 Supports Hematological Recovery
finance.yahoo.com - July 27 at 6:35 AM |
| Pluristem stock rises 2.5% on mid-stage clinical trial results
finance.yahoo.com - July 27 at 6:35 AM |
| This new drug could help the US survive a nuclear meltdown - MarketWatch
www.marketwatch.com - July 15 at 7:46 AM |
| A placenta cell medication could help the U.S. get through a nuclear meltdown
finance.yahoo.com - July 13 at 8:18 AM |
| Pluristem Therapeutics (PSTI) Advances Multinational Phase III Critical Limb Ischemia Study - StreetInsider.com
www.streetinsider.com - July 12 at 7:12 AM |
| Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Receives Buy Rating from Maxim Group
www.americanbankingnews.com - July 10 at 11:38 AM |
 | BRIEF-Pluristem Therapeutics says on July 7, co entered into an at market issuance sales agreement - SEC Filing
www.reuters.com - July 9 at 3:38 PM |
| Pluristem Therapeutics (PSTI) to Present New Data from ARS study at RITN Conference
www.streetinsider.com - July 1 at 6:45 AM |
 | Pluristem to Present New Data from ARS study at Radiology Conference in U.S.
feeds.benzinga.com - June 29 at 7:36 AM |
| Zacks: Analysts Anticipate Pluristem Therapeutics, Inc. (PSTI) to Announce -$0.07 Earnings Per Share
www.americanbankingnews.com - June 27 at 8:10 PM |
| Pluristem Therapeutics, Inc. (PSTI) Upgraded by Maxim Group to Buy
www.americanbankingnews.com - June 19 at 4:28 PM |
| Brokerages Expect Pluristem Therapeutics Inc. (PSTI) Will Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - June 1 at 6:32 PM |
| Pluristem Therapeutics Inc. (PSTI) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - May 29 at 8:32 AM |
| Pluristem Therapeutics Inc. (PSTI) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - May 23 at 7:28 PM |
| Pluristem Provides Shareholder Update on Corporate and Clinical Developments - GlobeNewswire (press release)
globenewswire.com - May 22 at 9:29 AM |
| Pluristem Provides Shareholder Update on Corporate and Clinical Developments
finance.yahoo.com - May 22 at 9:29 AM |
 | Pluristem reports 3Q loss
marketbeat.com - May 9 at 6:01 AM |
| -$0.07 Earnings Per Share Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter
www.americanbankingnews.com - May 8 at 1:12 PM |
| HC Wainwright Reiterates Buy Rating for Pluristem Therapeutics Inc. (PSTI)
www.americanbankingnews.com - May 7 at 10:02 AM |
| Pluristem Therapeutics Inc. (PSTI) Rating Reiterated by Maxim Group
www.americanbankingnews.com - May 7 at 7:34 AM |
Pluristem Therapeutics (PSTI) Chart for Thursday, September, 21, 2017
